Top Markets
#1 Derive Derive +31.22%
#2 Audiera Audiera +17.67%
#3 Humanity Humanity +10.75%
#4 Cross Cross +10.50%
#5 The Bitcoin Bull The Bitcoin Bull +10.48%
#6 Gama Token Gama Token +9.21%
#7 Geodnet Geodnet +8.73%
#8 Velvet Velvet +8.41%
#9 Biconomy Biconomy +7.49%
#10 Based Based +7.35%
Coin of the day
Derive Derive
Ustawienia
Język
POLSKI
Waluta
USD
Motyw
Dogwood Therapeutics, Inc. Dogwood Therapeutics, Inc.

Dogwood Therapeutics, Inc.

DWTX
Pozycja w akcjach #35719
Dogwood Therapeutics, Inc. is an emerging biotechnology firm dedicated to... Dogwood Therapeutics, Inc. is an emerging biotechnology firm dedicated to creating innovative antiviral treatments. Their primary goal is to address illnesses that stem from atypical immune reactions provoked by viral infections. Its leading therapeutic candidate, IMC-1, is a precise fixed-dose combination of famciclovir and celecoxib, engineered to combat fibromyalgia. Additionally, the company is advancing IMC-2, which blends valacyclovir and celecoxib, aiming to alleviate the array of symptoms linked to long COVID, including persistent fatigue, sleep disturbances, cognitive issues, pain, autonomic dysfunction, and anxiety. Previously operating as Virios Therapeutics, Inc., the organization adopted the name Dogwood Therapeutics, Inc. in October 2024. Established in 2012, the company maintains its main office in Alpharetta, Georgia.
Cena akcji
$1.84
Ostatnia synchronizacja: 2026-08-11
Kapitalizacja rynkowa
$3.51M
Zmiana (1 dzień)
0.46%
Zmiana (1 rok)
-62.71%
Kraj
US
Handel Dogwood Therapeutics, Inc. (DWTX)

Kategoria

Healthcare
Zyski dla Dogwood Therapeutics, Inc. (DWTX)
Zyski w 2026 TTM: 0
Według najnowszych raportów finansowych Dogwood Therapeutics, Inc., obecny zysk firmy wynosi 0. W roku 2026 firma osiągnęła zysk w wysokości 0, równa się zysku z roku 2026, który wynosił 0. Wyświetlany zysk to zysk przed odsetkami i podatkami, czyli EBIT.
Historia zysków firmy Dogwood Therapeutics, Inc. od 2026 do 2026
Zyski na koniec każdego roku
Rok Zyski Zmień
Za mało danych dla podanych dat.
Zyski podobnych firm lub konkurentów
Firma Zyski Różnica w zyskach Kraj
Vertex Pharmaceuticals Incorporated Vertex Pharmaceuticals Incorporated
Vertex Pharmaceuticals Incorporated
VRTX.US
$5.27B -
US
Argenx SE Argenx SE
Argenx SE
ARGX.US
$1.95B -
NL
Lonza Group AG Lonza Group AG
Lonza Group AG
LONN.SW
- -
CH
Samsung Biologics Co.,Ltd. Samsung Biologics Co.,Ltd.
Samsung Biologics Co.,Ltd.
207940.KS
- -
KR
UCB S.A. UCB S.A.
UCB S.A.
UCB.BR
$3.01B -
BE